{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:03:39Z","timestamp":1791223419479,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010800","name":"Hadassah Medical Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010800","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ahj.2018.01.012","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T13:14:18Z","timestamp":1518009258000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":136,"special_numbering":"C","title":["The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)\u2013TIMI 58 Trial"],"prefix":"10.1016","volume":"200","author":[{"given":"Stephen D.","family":"Wiviott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itamar","family":"Raz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofri","family":"Mosenzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri T","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avivit","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bansilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John PH","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid AM","family":"Gause-Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2018.01.012_bb0005","first-page":"e18","article-title":"Heart disease and stroke statistics\u20142011 update: a report from the American Heart Association","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.ahj.2018.01.012_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP15672.GLSUPPL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology\u2014clinical practice guidelines for developing a diabetes mellitus comprehensive care plan\u20142015","volume":"21","author":"Handelsman","year":"2015","journal-title":"Endocr Pract"},{"issue":"Suppl. 1","key":"10.1016\/j.ahj.2018.01.012_bb0015","first-page":"S4","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2018.01.012_bb0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(15)00044-3","article-title":"Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"3","author":"Udell","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2018.01.012_bb0030","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.01.012_bb0035","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.01.012_bb0040","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.01.012_bb0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamacardio.2016.0184","article-title":"The safety of dipeptidyl peptidase 4 inhibitors and the risk for heart failure","volume":"1","author":"Scirica","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2018.01.012_bb0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.310.6972.83","article-title":"13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years","volume":"310","author":"United Kingdom Prospective Diabetes Study (UKPDS)","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2018.01.012_bb0055","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2018.01.012_bb0060","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.01.012_bb0065","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2018.01.012_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004619","article-title":"The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials","volume":"4","author":"Sun","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.ahj.2018.01.012_bb0075","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.ahj.2018.01.012_bb0080","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2018.01.012_bb0085","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s40265-014-0324-3","article-title":"Dapagliflozin: a review of its use in patients with type 2 diabetes","volume":"74","author":"Plosker","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ahj.2018.01.012_bb0090","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc13-2955","article-title":"Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2018.01.012_bb0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","article-title":"Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis","volume":"15","author":"Sonesson","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ahj.2018.01.012_bb0100","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.01.012_bb0105","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ahj.2018.01.012_bb0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.01.012_bb0115","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIR.0000000000000156","volume":"132","author":"Hicks","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.01.012_bb0120","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/sim.3513","article-title":"A recycling framework for the construction of Bonferroni-based multiple tests","volume":"28","author":"Burman","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2018.01.012_bb0125","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/sim.3495","article-title":"A graphical approach to sequentially rejective multiple test procedures","volume":"28","author":"Bretz","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2018.01.012_bb0130","author":"Multipe endpoints in clinical trials guidance for industry (draft)"},{"key":"10.1016\/j.ahj.2018.01.012_bb0135","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.01.012_bb0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ejhf.633","article-title":"Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes","volume":"19","author":"Fitchett","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2018.01.012_bb0145","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2018.01.012_bb0150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1161\/CIRCULATIONAHA.116.022537","article-title":"Is the mortality benefit with empagliflozin in type 2 diabetes mellitus too good to be true?","volume":"134","author":"Kaul","year":"2016","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318300383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318300383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:00:20Z","timestamp":1757570420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870318300383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":29,"alternative-id":["S0002870318300383"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2018.01.012","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)\u2013TIMI 58 Trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2018.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}